Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980182676> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2980182676 endingPage "5361" @default.
- W2980182676 startingPage "5361" @default.
- W2980182676 abstract "Abstract Background: Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare subtype of Hodgkin Lymphoma (HL) that represents approximately 5% of HL and discloses a distinct clinical-pathological features with an overall good prognosis. Treatment strategies have been based on protocols for HL. Selected patients can be treated with surgery alone. Objective: Our aim was to describe the clinical characteristics, management and outcome of patients with NLPH. Methods: Between March 2000 and June 2016, 16 patients (14 M/2 F), median age: 9.8 (range 4.9-14.5) years, were consecutively diagnosed in our institution. Initial chemotherapy schedules were ABVD (Doxorubicin, Bleomycin, Vinblastine and Dacarbazine), COPP/ABVD or AV-PC (Adriamycin/Vincristine/Prednisone/Cyclophosphamide) were administered to 14 patients. When response was partial or null, additional chemotherapy was administered, IF-RT, Anti CD20 and/or HDC/Autologous SCT. A watch-and-wait strategy after lymph node complete surgery was used in two cases when this strategy became trustworthy. Results: Fourteen patients (87.5%) showed nodal compromise being cervical localization the most frequent localization. Thirteen patients (81.2%) presented localized disease (stage IA: 8, stage IB: 1, stage IIA:4) and 3 (18.7%) advanced disease (stage IIIA:1, stage IVA:1, IVB:1). Two patients had B symptoms. Two IA stage cases (12.5%) had complete node resection. Five patients (31.2%) received 4 cycles of ABVD. One patient (6.2%) received COPP/ABVD. Five patients (31,2%) received 3 cycles of AV-PC. One patient (6.2%) received 6 cycles of AV-PC plus 4 doses of Rituximab. One patient (6.2%) presented progressive disease after 3 cycles of ABVD, additional chemotherapy was administered and HDC/Autologous SCT. Three (18%) patients received IF-RT plus chemotherapy. One patient is still on treatment. Response to treatment was: CR in 12 pts (75%), Partial-response: 2 pts (12.5%), NR: 1 pts (6.2%). Median follow up: 58.4 (range 2-89) months. All patients remain in CR. Conclusion: Although the management of NLPHL was not uniform in our retrospective analysis, the results were promising. Watch and wait strategy plays an important role to avoid adverse effects associated with therapy. Tailored therapy according to staging and disease response, seemed to be a good strategy in our setting. Disclosures No relevant conflicts of interest to declare." @default.
- W2980182676 created "2019-10-18" @default.
- W2980182676 creator A5001380475 @default.
- W2980182676 creator A5023753770 @default.
- W2980182676 creator A5027394108 @default.
- W2980182676 creator A5052675162 @default.
- W2980182676 creator A5054576013 @default.
- W2980182676 creator A5061244751 @default.
- W2980182676 creator A5079587139 @default.
- W2980182676 creator A5088346031 @default.
- W2980182676 date "2016-12-02" @default.
- W2980182676 modified "2023-09-26" @default.
- W2980182676 title "Nodular Lymphocyte Predominant Hodgkin Lymphoma. Experience in a Single Institution in Argentina" @default.
- W2980182676 doi "https://doi.org/10.1182/blood.v128.22.5361.5361" @default.
- W2980182676 hasPublicationYear "2016" @default.
- W2980182676 type Work @default.
- W2980182676 sameAs 2980182676 @default.
- W2980182676 citedByCount "0" @default.
- W2980182676 crossrefType "journal-article" @default.
- W2980182676 hasAuthorship W2980182676A5001380475 @default.
- W2980182676 hasAuthorship W2980182676A5023753770 @default.
- W2980182676 hasAuthorship W2980182676A5027394108 @default.
- W2980182676 hasAuthorship W2980182676A5052675162 @default.
- W2980182676 hasAuthorship W2980182676A5054576013 @default.
- W2980182676 hasAuthorship W2980182676A5061244751 @default.
- W2980182676 hasAuthorship W2980182676A5079587139 @default.
- W2980182676 hasAuthorship W2980182676A5088346031 @default.
- W2980182676 hasConcept C121608353 @default.
- W2980182676 hasConcept C126322002 @default.
- W2980182676 hasConcept C141071460 @default.
- W2980182676 hasConcept C146357865 @default.
- W2980182676 hasConcept C151730666 @default.
- W2980182676 hasConcept C181199279 @default.
- W2980182676 hasConcept C185592680 @default.
- W2980182676 hasConcept C2776217839 @default.
- W2980182676 hasConcept C2776305933 @default.
- W2980182676 hasConcept C2776694085 @default.
- W2980182676 hasConcept C2776755627 @default.
- W2980182676 hasConcept C2777132456 @default.
- W2980182676 hasConcept C2779219270 @default.
- W2980182676 hasConcept C2779338263 @default.
- W2980182676 hasConcept C2779429289 @default.
- W2980182676 hasConcept C2779543040 @default.
- W2980182676 hasConcept C2779725641 @default.
- W2980182676 hasConcept C2780427987 @default.
- W2980182676 hasConcept C2780964509 @default.
- W2980182676 hasConcept C2781100745 @default.
- W2980182676 hasConcept C55493867 @default.
- W2980182676 hasConcept C71924100 @default.
- W2980182676 hasConcept C86803240 @default.
- W2980182676 hasConcept C90924648 @default.
- W2980182676 hasConceptScore W2980182676C121608353 @default.
- W2980182676 hasConceptScore W2980182676C126322002 @default.
- W2980182676 hasConceptScore W2980182676C141071460 @default.
- W2980182676 hasConceptScore W2980182676C146357865 @default.
- W2980182676 hasConceptScore W2980182676C151730666 @default.
- W2980182676 hasConceptScore W2980182676C181199279 @default.
- W2980182676 hasConceptScore W2980182676C185592680 @default.
- W2980182676 hasConceptScore W2980182676C2776217839 @default.
- W2980182676 hasConceptScore W2980182676C2776305933 @default.
- W2980182676 hasConceptScore W2980182676C2776694085 @default.
- W2980182676 hasConceptScore W2980182676C2776755627 @default.
- W2980182676 hasConceptScore W2980182676C2777132456 @default.
- W2980182676 hasConceptScore W2980182676C2779219270 @default.
- W2980182676 hasConceptScore W2980182676C2779338263 @default.
- W2980182676 hasConceptScore W2980182676C2779429289 @default.
- W2980182676 hasConceptScore W2980182676C2779543040 @default.
- W2980182676 hasConceptScore W2980182676C2779725641 @default.
- W2980182676 hasConceptScore W2980182676C2780427987 @default.
- W2980182676 hasConceptScore W2980182676C2780964509 @default.
- W2980182676 hasConceptScore W2980182676C2781100745 @default.
- W2980182676 hasConceptScore W2980182676C55493867 @default.
- W2980182676 hasConceptScore W2980182676C71924100 @default.
- W2980182676 hasConceptScore W2980182676C86803240 @default.
- W2980182676 hasConceptScore W2980182676C90924648 @default.
- W2980182676 hasIssue "22" @default.
- W2980182676 hasLocation W29801826761 @default.
- W2980182676 hasOpenAccess W2980182676 @default.
- W2980182676 hasPrimaryLocation W29801826761 @default.
- W2980182676 hasRelatedWork W160156331 @default.
- W2980182676 hasRelatedWork W1827095708 @default.
- W2980182676 hasRelatedWork W192469226 @default.
- W2980182676 hasRelatedWork W1941212132 @default.
- W2980182676 hasRelatedWork W2149011629 @default.
- W2980182676 hasRelatedWork W2293250840 @default.
- W2980182676 hasRelatedWork W2334705033 @default.
- W2980182676 hasRelatedWork W238056836 @default.
- W2980182676 hasRelatedWork W2426888873 @default.
- W2980182676 hasRelatedWork W2980182676 @default.
- W2980182676 hasVolume "128" @default.
- W2980182676 isParatext "false" @default.
- W2980182676 isRetracted "false" @default.
- W2980182676 magId "2980182676" @default.
- W2980182676 workType "article" @default.